JZJun Zhu

Jun Zhu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jun Zhu has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A bibliometric study on microenvironment-mediated drug resistance in interventional liver cancer treatment

    by Qiang Wang, Xu Feng, Guo Xiao, Yaoyong Chen, Quanji Yue, Zhongyao Chen, Yanjie Yang, Jun Zhu

    Microenvironment-driven drug resistance is a principal barrier to durable response after transarterial chemoembolisation, ablation or radioembolisation for hepatocellular carcinoma, yet the global structure of scholarship linking these domains remains undefined. This bibliometric analysis mapped 25-year publication trends, thematic evolution and collaboration networks at the intersection of interventional oncology, tumour microenvironment and therapeutic resistance. Web of Science Core Collection was searched (1 January 2000–31 December 2024) for records simultaneously referencing liver cancer, interventional therapy, microenvironmental descriptors and resistance terms. After dual-review screening, 939 articles and reviews were retained. Annual output, citation impact and Bradford-zone distributions were generated with bibliometrix 4.2.1. Bradford-zone analysis refers to the distribution of journal productivity, with journals in the first zone representing core literature, and those in subsequent zones reflecting peripheral or niche studies. This method helps assess the concentration of research in key journals and identifies areas of growth in the literature; co-authorship, journal-coupling and keyword-co-occurrence networks were rendered in VOSviewer 1.6.20. Workflow reproducibility was confirmed on a 5% subsample and by comparing fractional with full counting. Yearly publications rose from two in 2000 to 130 in 2024, amassing 36 095 citations (mean 38.4 per item). Output spikes in 2013, 2019 and 2021 paralleled seminal reports on hypoxia-driven angiogenesis, CAF activation, and COVID-19-related endothelial dysfunction. The pathophysiological mechanisms of COVID-19-induced endothelial injury, including cytokine-mediated endothelial dysfunction, have been implicated in compromising loco-regional therapies, contributing to resistance mechanisms that affect the efficacy of embolic treatments. China produced 47.3% of documents and sat at the nexus of global collaboration, with prominent links to the United States, Japan and South Korea. Cancer Research, Hepatology and Journal of Hepatology led citation rankings. Keyword overlays revealed a chronological shift from procedure-centric terms to microenvironmental and immunologic nodes—“angiogenesis”, “immune checkpoint”, “nanoparticles”—after 2017. Trend-topic mapping documented a transition from device optimisation toward mechanism-informed combination regimens incorporating anti-VEGF or PD-1 blockade. Research on microenvironment-mediated resistance in interventional liver-cancer therapy has expanded rapidly and pivoted toward molecularly targeted, immune-augmented strategies, driven chiefly by high-volume Chinese centres and trans-Pacific partnerships. Priorities now include single-cell analytics, radiomics-guided adaptive embolisation and multinational trials of combination therapy.

  • Open Access

    Combined transhepatic and transsplenic recanalization of chronic splenic vein occlusion to treat left-sided portal hypertension: A cases report

    by Jie Master Degree Liang, Xu Master Degree Feng, Min Master Degree Peng, Jin-Tao Master Degree Duan, Yao-Yong Master Degree Chen, Jun Master Degree Zhu

    Rationale: This report describes a unique case of a combination transhepatic and transsplenic recanalization of chronic splenic vein occlusion to treat left-sided portal hypertension (LSPH). Patient concerns: In this case report, we report a 49-year-old male who was admitted due to LSPH causing black stools for 2 days and vomiting blood for 1 hour. Diagnoses: The patient has a history of multiple episodes of pancreatitis in the past. After admission, abdominal contrast-enhanced CT scan showed the appearance of pancreatitis, with extensive splenic vein occlusion and accompanied by gastric varicose veins, indicating the formation of LSPH. Intervention: The patient received treatment with a combination of splenic and hepatic splenic venoplasty. Outcomes: Follow up for 1 year, CT and gastroscopy showed disappearance of gastric varices. Lessons: Splenic venoplasty is an effective method for treating LSPH. When it is difficult to pass through the occluded segment of the splenic vein through a single approach, percutaneous double approach splenic venoplasty can be attempted for treatment.


  • Open Access

    CLAG-M chemotherapy followed by umbilical cord blood stem cell transplantation for primary refractory acute myeloid leukaemia in a child: A case report

    by Jie Huang, Xiao-Yun Yang, Liu-Cheng Rong, Yao Xue, Jun Zhu, Yong-Jun Fang

    The prognosis of paediatric primary refractory/relapsed acute myeloid leukaemia (R/R AML) remains poor. Intensive therapy is typically used as salvage treatment for those with R/R AML. No data are currently available about the use of the CLAG-M protocol as salvage therapy in paediatric patients with R/R AML. An 8-year-old patient was diagnosed with acute myeloid leukaemia by bone marrow morphology and immunophenotype. The patient showed poor response to two cycles of induction therapy with 60% blast cells in the bone marrow after the second induction cycle. The patient achieved complete remission after being treated with the CLAG-M protocol as salvage therapy before undergoing umbilical cord blood stem cell transplantation. Morphological complete remission with haematological recovery has hitherto been maintained over 4 mo. Abnormal gene mutations detected at diagnosis were undetectable after haematopoietic stem cell transplantation. Here we present a paediatric patient with primary refractory acute myeloid leukaemia who was successfully treated with the CLAG-M protocol. Given the positive results of the presented patient, large-scale clinical studies are required to assess the role of the CLAG-M protocol in the salvage treatment of refractory or relapsed AML in childhood.